Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hamza Hashmi

Showing results (51-60 of 99) with videos related to

Pageof 10
Sort By:
European Journal of Haematology|February 21, 2024
Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-naïve relapsed multiple myelomaDanai Dima, Razan Mansour, James A Davis, et al.
European Journal of Haematology|December 4, 2023
Safety and efficacy of eltrombopag in patients with post-CAR T cytopeniasWilliam Wesson, Nausheen Ahmed, Aliya Rashid, et al.
JRSM Cardiovascular Disease|July 12, 2026
Angiography-derived physiology versus pressure wire-based fractional flow reserve for coronary revascularization guidance: A systematic review and meta-analysisMokshit Mehul Shah, Sarosh Fatima, Mariam Khachatryan, et al.
British Journal of Haematology|January 24, 2024
Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre studyDanai Dima, Aliya Rashid, James A Davis, et al.
Journal of Hematology|January 8, 2024
Impact of Cytogenetic Abnormalities, Induction and Maintenance Regimens on Outcomes After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma: A Decade-Long Real-World ExperienceAswani Thurlapati, William Wesson, James A Davis, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|January 3, 2024
Impact of age, obesity, and renal impairment on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myelomaKelly J Gaffney, Jonathan K Bakos, Arash Velayati, et al.
Transplantation and Cellular Therapy|April 14, 2024
ASTCT Committee on Practice Guidelines Survey on Evaluation and Management of Relapsed/Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T Cell TherapyHamza Hashmi, Ambuj Kumar, Mohamed A Kharfan-Dabaja, et al.
Blood Cancer Journal|March 11, 2025
A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myelomaRachel Dileo, Prerna Mewawalla, Kalaivani Babu, et al.
Annals of Hematology|October 18, 2023
Impact of race and ethnicity on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myelomaJames A Davis, Aswani Thurlapati, Erin Weeda, et al.
Transplantation and Cellular Therapy|November 11, 2023
Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular TherapyOlalekan O Oluwole, Bhagirathbhai Dholaria, Tristan E Knight, et al.
Pageof 10

Showing results (51-60 of 99) with videos related to

Sort By:
Pageof 10
European Journal of Haematology|February 21, 2024
Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-naïve relapsed multiple myelomaDanai Dima, Razan Mansour, James A Davis, et al.
European Journal of Haematology|December 4, 2023
Safety and efficacy of eltrombopag in patients with post-CAR T cytopeniasWilliam Wesson, Nausheen Ahmed, Aliya Rashid, et al.
JRSM Cardiovascular Disease|July 12, 2026
Angiography-derived physiology versus pressure wire-based fractional flow reserve for coronary revascularization guidance: A systematic review and meta-analysisMokshit Mehul Shah, Sarosh Fatima, Mariam Khachatryan, et al.
British Journal of Haematology|January 24, 2024
Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre studyDanai Dima, Aliya Rashid, James A Davis, et al.
Journal of Hematology|January 8, 2024
Impact of Cytogenetic Abnormalities, Induction and Maintenance Regimens on Outcomes After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma: A Decade-Long Real-World ExperienceAswani Thurlapati, William Wesson, James A Davis, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|January 3, 2024
Impact of age, obesity, and renal impairment on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myelomaKelly J Gaffney, Jonathan K Bakos, Arash Velayati, et al.
Transplantation and Cellular Therapy|April 14, 2024
ASTCT Committee on Practice Guidelines Survey on Evaluation and Management of Relapsed/Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T Cell TherapyHamza Hashmi, Ambuj Kumar, Mohamed A Kharfan-Dabaja, et al.
Blood Cancer Journal|March 11, 2025
A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myelomaRachel Dileo, Prerna Mewawalla, Kalaivani Babu, et al.
Annals of Hematology|October 18, 2023
Impact of race and ethnicity on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myelomaJames A Davis, Aswani Thurlapati, Erin Weeda, et al.
Transplantation and Cellular Therapy|November 11, 2023
Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular TherapyOlalekan O Oluwole, Bhagirathbhai Dholaria, Tristan E Knight, et al.
Pageof 10